Repair Biotechnologies develops first-in-class therapies based on the Cholesterol Degrading Platform (CDP)
CDP offers a safe approach to reversing the progression of important medical conditions that arise due to localized accumulations of excess cholesterol in the body. Our initial focus is on reversal of atherosclerosis, the build up of fatty plaques in arteries, and a condition that directly kills more than 25% of humanity via heart attack and stroke.
Towards an end to the mortality caused by atherosclerosis.
We have ambitious goals. CDP is an innovative platform and can be applied to many different indications that involve excess cholesterol in their pathology. These include multi-billion dollar markets with high unmet need, such as our primary focus of atherosclerosis. This includes the rare disease variants of accelerated atherosclerosis such as homozygous familial hypercholesterolemia (HoFH).
Our compelling preclinical evidence in animal models demonstrates the efficacy of CDP therapy: we can produce safe, rapid regression the atherosclerotic plaque that blocks arteries and similarly reverse the liver fibrosis characteristic of metabolic dysfunction-associated steatohepatitis (MASH). A clear path lies ahead towards becoming a platform company with multiple approved therapies.
Our investors are our partners in growth
Our investors fuel our progress towards bringing an end to cardiovascular mortality.
